Algert Global LLC Increases Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Algert Global LLC boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 84.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 86,140 shares of the company's stock after purchasing an additional 39,353 shares during the quarter. Algert Global LLC's holdings in Hims & Hers Health were worth $2,083,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in HIMS. Means Investment CO. Inc. increased its position in shares of Hims & Hers Health by 23.5% in the 4th quarter. Means Investment CO. Inc. now owns 50,040 shares of the company's stock valued at $1,210,000 after acquiring an additional 9,508 shares during the period. Raymond James Financial Inc. acquired a new stake in Hims & Hers Health during the 4th quarter worth about $18,048,000. State of Alaska Department of Revenue purchased a new stake in shares of Hims & Hers Health in the fourth quarter worth about $2,628,000. Pacer Advisors Inc. purchased a new position in Hims & Hers Health during the fourth quarter valued at approximately $374,000. Finally, Louisiana State Employees Retirement System purchased a new stake in Hims & Hers Health in the 4th quarter worth approximately $2,234,000. Hedge funds and other institutional investors own 63.52% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on HIMS shares. Truist Financial decreased their price objective on shares of Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research report on Thursday, April 10th. Leerink Partners lifted their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a report on Tuesday, February 25th. Morgan Stanley lowered their price objective on Hims & Hers Health from $60.00 to $40.00 and set an "equal weight" rating for the company in a research report on Tuesday, April 29th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating on shares of Hims & Hers Health in a research report on Wednesday. Finally, Canaccord Genuity Group lifted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and three have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Hold" and an average target price of $37.67.

Hims & Hers Health Stock Performance

Shares of NYSE:HIMS traded up $4.90 on Monday, hitting $56.86. 28,420,968 shares of the company's stock were exchanged, compared to its average volume of 18,398,398. The firm's 50-day moving average is $32.97 and its 200 day moving average is $32.51. The company has a market capitalization of $12.73 billion, a PE ratio of 128.69 and a beta of 1.84. Hims & Hers Health, Inc. has a 1-year low of $12.07 and a 1-year high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last announced its quarterly earnings results on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million for the quarter, compared to analyst estimates of $535.21 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Hims & Hers Health's revenue for the quarter was up 110.7% compared to the same quarter last year. During the same period last year, the business earned $0.05 EPS. On average, analysts anticipate that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, insider Soleil Boughton sold 4,152 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total transaction of $251,984.88. Following the transaction, the insider now directly owns 157,345 shares of the company's stock, valued at $9,549,268.05. This represents a 2.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Melissa Baird sold 67,687 shares of the company's stock in a transaction on Wednesday, February 12th. The shares were sold at an average price of $44.71, for a total value of $3,026,285.77. Following the completion of the sale, the chief operating officer now owns 706,872 shares in the company, valued at $31,604,247.12. This represents a 8.74% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 631,660 shares of company stock worth $24,978,043 over the last 90 days. 13.71% of the stock is currently owned by insiders.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.